The Middle East and North Africa (MENA) region is undergoing a significant transformation in its pharmaceutical and healthcare industries, positioning itself as an emerging hub for manufacturing, research, and innovation. Once heavily reliant on imports, the region is now advancing rapidly toward self-reliance and strategic integration into global supply chains. Driven by strong demographic growth, urbanization, and the rising prevalence of non-communicable diseases (NCDs), MENA governments are prioritizing healthcare spending, universal coverage, and localized pharmaceutical production as part of broader economic diversification agendas.

For example, Saudi Arabia has expanded its pharmaceutical factories to 56 as of 2024, with the goal of meeting 40% of domestic demand through local production by 2030 under Vision 2030. Similarly, the UAE has built 23 pharmaceutical facilities and is expanding its focus on precision medicine, biologics, and orphan drugs. Egypt, with its established base of approximately 190 factories, already manufactures 94% of its domestic pharmaceutical needs and is growing into a leading regional exporter. In parallel to these manufacturing advances, R&D is evolving from a generics-driven base toward biologics, biosimilars, and digital innovation. National genome programs, expanded clinical trial frameworks, and partnerships with multinational corporations are accelerating this shift while digital health infrastructure enables real-world data collection to support research and innovation.